Ruiz-Casas, Leonardo
Evans, Jonathan http://orcid.org/0000-0002-3490-7191
Rose, Alison
Pedra, Gabriel Ghizzi
Lobo, Alan
Finnegan, Alan
Hayee, Bu
Peyrin-Biroulet, Laurent
Sturm, Andreas
Burisch, Johan
Terry, Helen
Avedano, Luisa
Tucknott, Seb
Fiorino, Gionata
Limdi, Jimmy
Funding for this research was provided by:
Pfizer UK
Eli Lilly and Company
Celgene
Article History
Received: 21 August 2020
Accepted: 15 November 2021
First Online: 4 December 2021
Change Date: 15 December 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12876-021-02062-3
Declarations
:
: Ethics approval was provided by the University of Chester research ethics committee. All patients provided consent to participate in the study.
: Not applicable.
: JB reports personal fees from AbbVie, personal fees from Janssen-Cilag, personal fees from Celgene, personal fees from MSD, personal fees from Pfizer, Grants and personal fees from Takeda, Grants and personal fees from Tillots Pharma, personal fees from Samsung Bioepis, outside the submitted work. JL has received research support from Takeda and consultancy and speaker fees from Abbvie, MSD, Janssen, Pfizer and Takeda. LPB reports personal fees from AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boerhinger Ingelheim, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine; Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Enthera, Theravance; Grants from Abbvie, MSD, Takeda; stock options: CTMA. The remaining authors declare no competing interests.